- In March 2025, researchers at Moffitt Cancer Center developed a dendritic cell vaccine targeting HER2-positive, estrogen receptor-negative breast cancer. Early studies suggest it can enhance chemotherapy effectiveness in this aggressive cancer subtype
- In January 2025, DOC1021, an autologous dendritic cell vaccine, demonstrated a 93% 12-month survival rate in glioblastoma patients. The vaccine has received FDA Fast Track and Orphan Drug designations, with a Phase 2 trial expected to begin in Q1 2025
- In December 2024, the FDA granted Fast Track designation to Diakonos Oncology's dendritic cell vaccine for pancreatic ductal adenocarcinoma. This vaccine aims to activate robust immune responses without modifying the patient's cells
- In September 2024, a first-in-human clinical trial commenced for WDVAX, a dendritic cell vaccine incorporating autologous tumor cell lysate, to evaluate its safety and immunogenicity in patients with advanced cancers
